Literature DB >> 25836945

Effects of sitagliptin on the serum creatinine in Japanese type 2 diabetes.

Hajime Maeda1, Akira Kubota2, Akira Kanamori2, Yasushi Tanaka3, Yasuo Terauchi4, Ikuro Matsuba2.   

Abstract

We found a slight elevation of serum creatinine in the subjects treated with sitagliptin for 2 years and a correlation between creatinine elevation and HbA1c reduction. These results suggest that creatinine elevation is associated with activation of incretin, most possibly with up-regulation of diuretic activity of GLP-1.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Creatinine; Dipeptidyl peptidase-4 (DPP-4) inhibitor; HbA1c; Sitagliptin

Mesh：

Substances：

Year:  2015        PMID： 25836945     DOI： 10.1016/j.diabres.2015.03.008

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN： 0168-8227            Impact factor:   5.602


  7 in total

1.  The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.

Authors:  Koichi Kanozawa; Yuichi Noguchi; Souichi Sugahara; Satoko Nakamura; Hirohisa Yamamoto; Keiko Kaneko; Rika Kono; Saeko Sato; Tomonari Ogawa; Hajime Hasegawa; Shigehiro Katayama
Journal:  Clin Exp Nephrol       Date:  2017-12-23       Impact factor: 2.801

2.  Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study.

Authors:  Shinichi Umezawa; Akira Kubota; Hajime Maeda; Akira Kanamori; Kiyokazu Matoba; Yasuyuki Jin; Fuyuki Minagawa; Mitsuo Obana; Kotaro Iemitsu; Shogo Ito; Hikaru Amamiya; Mizuki Kaneshiro; Masahiko Takai; Hideaki Kaneshige; Kazuhiko Hoshino; Masashi Ishikawa; Nobuaki Minami; Tetsuro Takuma; Nobuo Sasai; Sachio Aoyagi; Takehiro Kawata; Atsuko Mokubo; Yukiko Miyairi; Hiroshi Takeda; Shin Honda; Hideo Machimura; Tetsuya Motomiya; Manabu Waseda; Yoshikazu Naka; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba
Journal:  BMC Endocr Disord       Date:  2015-07-03       Impact factor: 2.763

3.  Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study.

Authors:  Osamu Tomonaga; Hiroshi Sakura; Naotake Hashimoto; Kazuo Sasamoto; Hiroshi Ohashi; Sumiko Hasumi; Noriko Ujihara; Tadasu Kasahara; Hideo Nunome; Masashi Honda; Yasuhiko Iwamoto
Journal:  J Clin Med Res       Date:  2017-12-01

4.  Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study.

Authors:  Masahiko Takai; Masashi Ishikawa; Hajime Maeda; Akira Kanamori; Akira Kubota; Hikaru Amemiya; Takashi Iizuka; Kotaro Iemitsu; Tomoyuki Iwasaki; Goro Uehara; Shinichi Umezawa; Mitsuo Obana; Hideaki Kaneshige; Mizuki Kaneshiro; Takehiro Kawata; Nobuo Sasai; Tatsuya Saito; Tetsuo Takuma; Hiroshi Takeda; Keiji Tanaka; Shigeru Nakajima; Kazuhiko Hoshino; Shin Honda; Hideo Machimura; Kiyokazu Matoba; Fuyuki Minagawa; Nobuaki Minami; Yukiko Miyairi; Atsuko Mokubo; Tetsuya Motomiya; Manabu Waseda; Masaaki Miyakawa; Yasuo Terauchi; Yasushi Tanaka; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2019-04-14

5.  Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.

Authors:  Hiroshi Takeda; Nobuo Sasai; Shogo Ito; Mitsuo Obana; Tetsuo Takuma; Masahiko Takai; Hideaki Kaneshige; Hideo Machimura; Akira Kanamori; Kazumi Nakajima; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2015-12-28

6.  Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.

Authors:  Shouhei Yuasa; Kazuyoshi Sato; Masahiko Takai; Masashi Ishikawa; Shinichi Umezawa; Akira Kubota; Hajime Maeda; Akira Kanamori; Masaaki Miyakawa; Yasushi Tanaka; Yasuo Terauchi; Ikuro Matsuba
Journal:  J Clin Med Res       Date:  2016-05-25

7.  Sitagliptin on carotid intima-media thickness in type 2 diabetes and hyperuricemia patients: a subgroup analysis of the PROLOGUE study.

Authors:  Yipin Zhao; Huawei Wang; Dazhi Ke; Wei Deng; Yingying Ji; Jiaojiao Yang; Zebin Lin; Guoxing Li; Li Xiao; Jianmin Tang; Qingwei Chen
Journal:  Ther Adv Chronic Dis       Date:  2021-06-22       Impact factor: 5.091
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.